EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment

Domiziana Masci iD, Chiara Naro iD, Michela Puxeddu, Andrea Urbani, Claudio Sette, Giuseppe La Regina iD, Romano Silvestri iD

Molecules · 09.11.2023 · 28 (22) · 7513

DOI: 10.3390/molecules28227513 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 09.11.2023. Verfasst von Domiziana Masci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco V…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 294 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Now, Associazione Italiana Ricerca sul Cancro, AIRC IG 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very difficult to treat due to the lack of an effective targeted therapy. However, recent advances in the molecular characterization of TNBC are encouraging the development of novel drugs and therapeutic combinations for its therapeutic management. In the present review, we will provide an overview of the currently available standard therapies and new emerging therapeutic strategies against TNBC, highlighting the promises that newly developed small molecules, repositioned drugs, and combination therapies have of improving treatment efficacy against these tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsHumansCombined Modality TherapyDrug Discovery

Stichwörter der Autor:innen

PARPantibody drug conjugatescancercombination therapydrug resistanceinhibitorskinasesmicrotubulestriple-negative breast cancer

Autor:innen und Institutionen

  • Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy.
  • Department of Neurosciences, Section of Human Anatomy, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy.
  • GSTeP-Organoids Research Core Facility, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.
  • Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.

ORCID-Profile: Domiziana Masci, Chiara Naro, Giuseppe La Regina, Romano Silvestri

Förderung

  • Breast Cancer Now
  • Associazione Italiana Ricerca sul Cancro
  • AIRC IG 2020
  • MIUR PRIN 2022
  • Sapienza University of Rome
  • The Università Cattolica del Sacro Cuore

Zitieren

APA

Masci, D., Naro, C., Puxeddu, M., Urbani, A., Sette, C., La Regina, G., & Silvestri, R. (2023). Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment. Molecules, 28(22), 7513. https://doi.org/10.3390/molecules28227513

Vancouver

Masci D, Naro C, Puxeddu M, Urbani A, Sette C, La Regina G, et al. Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment. Molecules. 2023;28(22):7513. doi:10.3390/molecules28227513

BibTeX
@article{Masci2023,
  author = {Masci, Domiziana and Naro, Chiara and Puxeddu, Michela and Urbani, Andrea and Sette, Claudio and La Regina, Giuseppe and Silvestri, Romano},
  title = {Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {22},
  pages = {7513},
  doi = {10.3390/molecules28227513}
}
Kostenlos starten →